antiviral and associated therapy - versus placebo - for COVID-19 mild to moderate pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 0.12 [0.01, 2.36]< 10%1 study (1/-)91.6 %NAnot evaluable crucial-
clinical improvement (7-day) 0.90 [0.77, 1.06]> 10%1 study (1/-)9.7 %NAnot evaluable important-
clinical improvement (time to event analysis only) 1.40 [0.91, 2.15]> 10%1 study (1/-)93.8 %NAnot evaluable important-
hospital discharge 1.20 [0.73, 1.98]> 10%1 study (1/-)76.3 %NAnot evaluable important-
mechanical ventilation 0.20 [0.00, 8.69]< 10%1 study (1/-)79.4 %NAnot evaluable important-
viral clearance 0.92 [0.77, 1.09]> 10%1 study (1/-)17.3 %NAnot evaluable important-
viral clearance by day 7 0.91 [0.77, 1.08]> 10%2 studies (2/-)13.7 %lownot evaluable highimportant-
ICU admission 0.90 [0.30, 2.70]< 10%1 study (1/-)57.4 %NAnot evaluable non important-

safety endpoints 00

serious adverse events 2.80 [0.14, 56.95]< 10%1 study (1/-)25.4 %NAnot evaluable important-
adverse events 4.78 [0.26, 87.65]< 190%2 studies (2/-)14.9 %some concernnot evaluable moderatenon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.